Stockreport

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Therapeutics Ltd. - Ordinary Shares  (NRSN) 
PDF 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALSStatistically significant survival benefit demonstrated, includi [Read more]